Background: Studies have suggested an association between heavy metal exposures, including lead, and Parkinson’s disease (PD) using reconstructed exposure histories, but only one used bone lead—a biomarker of cumulative lead exposure, and found a non-significant increasing risk of PD with increasing bone lead. Objectives: We sought to assess the association between bone lead and...
Background: Human exposure to inorganic arsenic, a potent oxidative stressor, causes various dermal disorders, including hyperkeratosis and skin cancer. Nuclear factor E2-related factor 1 (NRF1) plays a critical role in regulating the expression of many antioxidant response element (ARE)-dependent genes. Objectives: Investigate the role of NRF1 in arsenic-induced antioxidant response and cytotoxicity in human...
ST. PAUL, Minn.–NEWS–St. Jude Medical, Inc. (NYSE:STJ) applauds the updated class and level of evidence for Fractional Flow Reserve (FFR)-guided treatment in the Guidelines on Percutaneous Coronary Intervention (PCI) announced Monday at the European Society of Cardiology (ESC) congress in Stockholm. Supporting this change are the very strong one and two year data from...
ST. PAUL, Minn.–NEWS–St. Jude Medical, Inc. (NYSE:STJ) applauds the updated class and level of evidence for Fractional Flow Reserve (FFR)-guided treatment in the Guidelines on Percutaneous Coronary Intervention (PCI) announced Monday at the European Society of Cardiology (ESC) congress in Stockholm. Supporting this change are the very strong one and two year data from...
IRVINE, Calif.–NEWS–Allergan, Inc. (NYSE:AGN) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN® (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN® 0.01% is an optimized reformulation of LUMIGAN® (bimatoprost ophthalmic solution) 0.03%....
IRVINE, Calif.–NEWS–Allergan, Inc. (NYSE:AGN) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN® (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN® 0.01% is an optimized reformulation of LUMIGAN® (bimatoprost ophthalmic solution) 0.03%....
TOLEDO, Ohio–NEWS–Health Care REIT, Inc. (NYSE:HCN) today announced plans to redeem all 313,972 shares of its 7.5% Series G Cumulative Convertible Redeemable Preferred Stock (NYSE: HCN PrG, CUSIP: 42217K 502) on September 30, 2010 at a redemption price of $25.00 per share plus accrued and unpaid dividends through September 30, 2010. The Notice of...
TOLEDO, Ohio–NEWS–Health Care REIT, Inc. (NYSE:HCN) today announced plans to redeem all 313,972 shares of its 7.5% Series G Cumulative Convertible Redeemable Preferred Stock (NYSE: HCN PrG, CUSIP: 42217K 502) on September 30, 2010 at a redemption price of $25.00 per share plus accrued and unpaid dividends through September 30, 2010. The Notice of...